G1 Therapeutics to Present at Biotech Showcase 2014
Corporate overview to be given January 13 at 9:15 a.m. PST
CHAPEL HILL, N.C., Jan. 8, 2014 /PRNewswire/ -- G1 Therapeutics, Inc. today announced that Dr. Seth Rudnick, executive chairman of the company's board of directors, will present a corporate overview at Biotech Showcase 2014, which is being held January 13-15 in San Francisco, CA. Dr. Rudnick and members of G1's senior scientific team will be available to respond to questions and participate in one-on-one meetings with investors attending the conference.
Details of the presentation are as follows:
Date: Monday, January 13
Time: 9:15 a.m. PST
Location: Parc 55 Wyndham – Union Square, San Francisco, CA
More information about Biotech Showcase 2014 can be found at www.ebdgroup.com/bts.
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc. is a privately held pharmaceutical company based in Chapel Hill, NC that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications. These molecules are being developed for targeting specific proteins associated with cell proliferation and growth. Such therapies may be useful to protect the bone marrow and other organs, including the kidney and lung, from toxic insult. In October 2013, the company raised $12.5 million in a Series A financing led by MedImmune Ventures that will enable it to advance its lead clinical candidate into clinical trials for the potential treatment of chemotherapy induced myelosuppression. Visit www.g1therapeutics.com for more information.
SOURCE G1 Therapeutics, Inc.
More by this Source
G1 Therapeutics to Share New Research Findings at AACR Annual Meeting 2014
Mar 27, 2014, 09:00 ET
Dr. Seth Rudnick Joins G1 Therapeutics as Executive Chairman
Jan 07, 2014, 09:00 ET
G1 Therapeutics to Present at Southeast BIO Investor & Partnering Forum
Nov 01, 2013, 09:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.